Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
VZ$46.75+0.58(+1.26%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.33+0.47(+0.46%)Transaction in Own Shares8:00:53 AM ETISRG$483.40+1.21(+0.25%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETAAPL$354.62+5.11(+1.46%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$217.02+17.56(+8.80%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.25+1.93(+0.76%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETAAPL$354.62+5.11(+1.46%)Apple: Demand Is Not The Problem7:54:50 AM ETMCD$282.00+1.78(+0.64%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.05-4.65(-2.71%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$556.84+1.04(+0.19%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ETQCOM$155.00-18.19(-10.50%)Wall Street Breakfast Podcast: The VIX Plunges In Post-Election Rally7:47:00 AM ETKO$97.10+1.22(+1.27%)If You'd Invested $1,000 Alongside Warren Buffett in Coca-Cola, Here's How Much You'd Have Today7:47:00 AM ETQCOM$155.00-18.19(-10.50%)Qualcomm Q4: This Dip Is Not The One To Buy Yet7:45:04 AM ETAXP$337.65+5.03(+1.51%)American Express vs. PayPal: Which Financial Stock Is a Better Buy for 2027?7:45:01 AM ETSPCX$132.37-3.55(-2.61%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETUBER$72.15+2.25(+3.22%)Amazon and Uber Want to Bring You Your Next Meal. The Delivery Turf War Is Escalating.7:43:00 AM ETCOP$139.45+2.51(+1.83%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$165.25+2.20(+1.35%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$139.45+2.51(+1.83%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$634.70+4.70(+0.75%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$354.62+5.11(+1.46%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$376.34-8.85(-2.30%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ET

RCEL · NASDAQ

AVITA Medical, Inc.

$16.09 -0.19 (-1.17%)

Company overview

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetic indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is the RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$400M
Employees
260
Headquarters
Valencia, CA
Website
avitamedical.com
CEO
Cary G. Vance
Listed
May 14, 2012
P/E
-10.25
Dividend yield
0.00%

Company financials

Revenue
$72.3M
Gross profit
$58.9M
Operating income
-$39.5M
EBITDA
-$37.7M
Net income
-$45.3M
EPS
-$1.57
Total assets
$51.5M
Total debt
$2M
Gross margin
81.36%
Net margin
-62.67%
Earnings yield
-9.76%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

3.206.7610.3113.8717.43
RCEL 1D NASDAQ O15.83H16.59L15.62C16.28+0.95 (+6.20%)Vol473.86K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
RCELAVITA Medical, Inc. Press release AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 GlobeNewswire
RCELAVITA Medical, Inc. Press release AVITA Medical to Announce Third Quarter 2026 Financial Results GlobeNewswire
RCELAVITA Medical, Inc. Stock news Is AVITA Medical Inc (RCEL) Overvalued After 5.9% Rally? GF Value Says Overvalued GuruFocus
RCELAVITA Medical, Inc. Stock news NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL Defense World
RCELAVITA Medical, Inc. Stock news AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
RCELAVITA Medical, Inc. Press release AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference GlobeNewswire
RCELAVITA Medical, Inc. Stock news All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy Zacks Investment Research
RCELAVITA Medical, Inc. Stock news Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy? Zacks Investment Research
RCELAVITA Medical, Inc. Stock news AVITA Medical: Favorable Reimbursements For Skin Wound Care Seeking Alpha
RCELAVITA Medical, Inc. Stock news Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft MarketBeat
RCELAVITA Medical, Inc. Stock news AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript Seeking Alpha
RCELAVITA Medical, Inc. Press release AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes GlobeNewswire
RCELAVITA Medical, Inc. Stock news Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% MarketBeat
RCELAVITA Medical, Inc. Stock news Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds MarketBeat
RCELAVITA Medical, Inc. Stock news AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript Seeking Alpha
RCELAVITA Medical, Inc. Press release AVITA Medical to Host Investor Webinar Briefing GlobeNewswire
RCELAVITA Medical, Inc. Press release AVITA Medical Announces Participation at Canaccord Genuity Growth Conference GlobeNewswire
RCELAVITA Medical, Inc. Stock news This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Benzinga
RCELAVITA Medical, Inc. Stock news Avita Medical Q2 Earnings Call Highlights MarketBeat
RCELAVITA Medical, Inc. Stock news AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about AVITA Medical, Inc.

What does AVITA Medical, Inc. do?
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetic indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is the RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older.
What is RCEL's market cap?
AVITA Medical, Inc. (RCEL) is a listed stock with a live quote. The latest market cap on this page is $400M.
Where is AVITA Medical, Inc. headquartered?
AVITA Medical, Inc. is headquartered in Valencia, CA.
How do I get RCEL news from the API?
Call GET /v1/news?tickers=RCEL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does RCEL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RCEL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the RCEL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs